Key facts
- This page summarizes Steve Elms's Form 4 filing for ADMA BIOLOGICS, INC. (ADMA).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 28 Feb 2024, 21:00.
Steve Elms - 26 Feb 2024 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)
- Reporting relationship
- Director
- Issuer ticker
- ADMA
- Reported as of
- 26 Feb 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 28 Feb 2024, 21:00:31 UTC
- Prior SEC filing
- 08 Jun 2023
- Next SEC filing
- 15 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steve Elms, by Brian Lenz as Attorney-in-fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steve Elms filed Form 4 for ADMA BIOLOGICS, INC. (ADMA) on 28 Feb 2024.
Change
- Previous filing in this sequence was filed on 08 Jun 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADMA
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +24,040
- Change %
- +46%
- Price
- $0.000000
- Shares after
- 76,441
- Date
- 26 Feb 2024
- Ownership
- Direct
- Footnotes
- F1, F2
ADMA
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 3,615,671
- Date
- 26 Feb 2024
- Ownership
- See footnote
- Footnotes
- F3
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
ADMA
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +37,541
- Change %
- Price
- $0.000000
- Shares after
- 37,541
- Date
- 26 Feb 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 37,541
- Exercise price
- $5.40
- Footnotes
- F4
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 4 footnotes
Footnote F1
These shares represent restricted stock units ("RSUs") that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date.
Footnote F2
Includes, as of the transaction date, (i) 24,040 RSUs granted on February 26, 2024 and reported on this Form 4, subject to vesting as set forth in footnote (1); (ii) 25,815 RSUs granted on March 6, 2023, which will vest in full on March 6, 2024; and (iii) 26,586 shares of common stock owned by the reporting person.
Footnote F3
These shares are owned by Aisling Capital II LP ("Aisling"). Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon.
Footnote F4
The options vest in 12 equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant.